| Press releases

Formycon Publishes Figures for the First Quarter of 2016

The first quarter of 2016 has been successful for Formycon both in operational and financial terms. On the furthest-progressed development project FYB201, a biosimilar candidate for Lucentis®*, the first patient was enrolled in February of this year in the phase III study

Calendar

Annual General Meeting 2016

Annual General Meeting of Formycon AG on 2nd of June 2016 in Planegg/Munich

Financial reports
myr15-teaser

Mid-Year Report 2015

Published on 14. September 2015

  • buchner_en
  • slider02
  • slider03
  • slider04
  • slider05
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has three biosimilars under development, with further product candidates already identified. Two biosimilar candidates have been licensed out to Santo Holding GmbH.